Abstract：
Drug-induced nephrolithiasis can arise from insoluble components within medications or crystallization of metabolites due to changes in metabolism and urinary pH. The connection between drugs utilized for iron chelation therapy (ICT) and nephrolithiasis is not well understood. In this report, we describe two pediatric patients diagnosed with nephrolithiasis while undergoing treatment with the chelating agents deferasirox, deferiprone, and deferoxamine for iron overload secondary to repeat blood transfusion.
摘要：
药物诱导的肾结石可由药物中的不溶性成分或由于代谢和尿pH的变化而导致的代谢物结晶引起。用于铁螯合疗法（ICT）的药物与肾结石之间的联系尚不清楚。在这份报告中,我们描述了两名诊断为肾结石的儿科患者，同时接受螯合剂地拉罗司治疗，去铁酮，和去铁胺用于重复输血继发的铁超负荷。
